News Author: HT Staff Publish date: July 3, 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of caplacizumab (Cablivi) for the treat...
News Author: HT Staff Publish date: July 2, 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of tisagenlecleucel (Kymriah®, f...
News Author: HT Staff Publish date: July 2, 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the chimeric antigen receptor (C...
News Author: HT Staff Publish date: July 2, 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approved use of tocilizumab (RoAct...
News Author: HT Staff Publish date: July 2, 2018
The US Food and Drug Administration (FDA) has lifted the clinical hold on a phase 1b trial of APTO-253.
APTO-253 is a small molecule that inhibits ...
News Author: HT Staff Publish date: June 29, 2018
STOCKHOLM—Interim trial results suggest the EZH2 inhibitor tazemetostat can produce durable responses in patients with relapsed or refractory folli...
News Author: HT Staff Publish date: June 29, 2018
The US Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613 for the treatment of Burkitt lymphoma (BL). CPI-613 is a n...
News Author: HT Staff Publish date: June 28, 2018
A survey of more than 15,000 childhood cancer survivors (CCSs) revealed that many were unconcerned about their risk of health problems.
Thirty-one ...
News Author: HT Staff Publish date: June 28, 2018
The US Food and Drug Administration (FDA) has accepted for priority review a new drug application (NDA) for glasdegib, an oral SMO inhibitor.
With ...
News Author: HT Staff Publish date: June 27, 2018
Patients who receive red blood cell (RBC) transfusions before, during, or immediately after surgery may have an increased risk of venous thromboemboli...
News Author: HT Staff Publish date: June 27, 2018
Erytech Pharma said it plans to stop development of eryaspase for acute lymphoblastic leukemia (ALL).
This means withdrawal of the European marketi...
News Author: HT Staff Publish date: June 26, 2018
STOCKHOLM—An ongoing phase 2 study suggests voxelotor (GBT440) can benefit adolescents with sickle cell disease (SCD).
In the HOPE-KIDS 1 study, vo...
News Author: HT Staff Publish date: June 26, 2018
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ibrutinib (Imbruvica®) to be...
News Author: HT Staff Publish date: June 26, 2018
George Stamatoyannopoulos, MD, who conducted important research into hemoglobinopathies, passed away this month at the age of 84.
Dr Stamatoyannopo...
News Author: HT Staff Publish date: June 25, 2018
STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM).
In the phase 1 EXPLORER ...
